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Abstract
Background: Osteosarcoma is the most common malignant bone tumor in children and young adults that produces
aberrant osteoid. The aim of this study was to assess the utility of 2-deoxy-2-[18F-] fluoro-D-glucose ([18F] FDG) and
sodium [18F] Fluoride (Na [18F] F) PET scans in orthotopic murine models of osteosarcoma to describe the metabolic
pattern of the tumors, to detect and diagnose tumors and to evaluate the efficacy of a new treatment
based in oncolytic adenoviruses.
Methods: Orthotopic osteosarcoma murine models were created by the injection of 143B and 531MII cell
lines. [18F]FDG and Na [18F] F PET scans were performed 30 days (143B) and 90 days (531MII) post-injection.
The antitumor effect of two doses (107 and 108 pfu) of the oncolytic adenovirus VCN-01 was evaluated in
531 MII model by [18F] FDG PET studies. [18F] FDG uptake was quantified by SUVmax and Total Lesion Glycolysis (TLG)
indexes. For Na [18F] F, the ratio tumor SUVmax/hip SUVmax was calculated. PET findings were confirmed by
histopathological techniques.
Results: The metabolic pattern of tumors was different between both orthotopic models. All tumors showed [18F] FDG
uptake, with a sensitivity and specificity of 100%. The [18F] FDG uptake was significantly higher for the 143B
model (p < 0.001). Sensitivity for Na [18F] F was around 70% in both models, with a specificity of 100%. 531MII tumors
showed a heterogeneous Na [18F] F uptake, significantly higher than 143B tumors (p < 0.01). Importantly, [18F] FDG and
Na [18F] F uptake corresponded to highly cellular or osteoid-rich tumors in the histopathological analysis, respectively.
[18F] FDG data confirmed that the oncolytic treatment of 531MII tumors produced a significant reduction in growth
even with the 107 pfu dose.
Conclusions: PET studies demonstrated that the different osteosarcoma xenograft models developed tumors with
diverse metabolic patterns that can be described by multitracer PET studies. Since not all tumors produced abundant
osteoid, [18F] FDG demonstrated a better sensitivity for tumor detection and was able to quantitatively monitor in vivo
response to the oncolytic adenovirus VCN-01.
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Background
Osteosarcoma is the most common primary malignant
bone tumor. This aggressive tumor of mesenchymal
origin produces aberrant osteoid and is the most fre-
quent skeletal neoplasm in children and adolescents,
being the third most common cancer in this age
group [1]. The primary tumors mainly occur in the
long bones of the extremities near the metaphyseal
growth plate and, at initial diagnosis, most patients
present micrometastatic disease and an additional 15–
20% have visible metastases.
Currently, the therapeutic strategy includes neo- and
adjuvant chemotherapy combined with surgical removal
of detectable disease [2], but the long-term outcome for
patients with detectable metastases is still insufficient.
Therefore, multiple new therapeutic approaches have
been developed to improve clinical outcome for meta-
static patients [3].
In the clinical setting, positron emission tomography
(PET) has emerged as a new potent tool in the manage-
ment of osteosarcoma. The main advantage of PET com-
pared to other structural imaging techniques like MRI
or CT is that it can not only detect tumors, but also
offer quantitative metabolic information with prognostic
value. By large, the glucose analog 2-deoxy-2-[18F]
fluoro-D-glucose ([18F] FDG) is the most commonly
used radiotracer to detect tumors, including osteosar-
coma [4], based on the increased glucose metabolism of
malignant cells. In osteosarcoma, [18F] FDG PET/CT
helps to detect recurrences in patients with suspicious of
relapse after treatment [5], being more sensitive than
bone scintigraphy in detecting bone metastases [6].
Moreover a decrease in PET semi-quantitative indexes
predicts poor response to treatment even after the first
cycle of neoadjuvant chemotherapy in sarcoma and
osteosarcoma [7, 8]. Consequently, [18F] FDG PET/CT
can provide critical information about treatment plan-
ning.. In addition to [18F] FDG, other PET radiotracers
can offer complementary information about the meta-
bolic pattern and phenotype of the tumors. Among
these, sodium [18F] fluoride (Na [18F] F) is of particular
interest because it is a positron-emitting bone-seeking
agent that mainly reflects remodeling of bone. It can
hence be used to image different bone diseases [9] and
potentially the osteoblastic mineralization that occurs
during osteosarcoma growth. In animal models of osteo-
sarcoma, the combination of [18F] FDG and Na [18F]
FPET radiotracers is able to describe the different meta-
bolic features of tumors, distinguishing between the
osteolytic and osteoblastic phenotypes [10–12]. The cap-
acity of PET to describe in vivo and non-invasively the
tumor metabolism is therefore of great interest for the
study of new treatments in animal models, and in the
clinical setting, it could allow in the future to select
personalized treatments based on the biologic features
of osteosarcomas [13, 14].
The aim of this study was to further explore the ability
of PET to detect and describe the metabolic pattern of
osteosarcoma tumors, as well as its usefulness to evalu-
ate the efficacy of new treatments. [18F] FDG and Na
[18F] F radiotracers were used in two different orthotopic
intratibial mouse models of osteosarcoma, obtained with
a commercial (143B) and a primary osteosarcoma-de-
rived (531MII) cell lines. Both radiotracers were
employed to describe the metabolic phenotype of tumors
and to calculate their sensitivity and specificity for de-
tecting osteosarcomas. In addition, [18F]FDG was used
to assess the response to different doses of a new experi-
mental treatment based on the oncolytic adenovirus
VCN-01 [15].
Methods
Cell lines
The human osteosarcoma cell line 143B was obtained
from the American Type Culture Collection (ATCC®
CRL8303™). Cell line 531MII was developed at the Uni-
versity Clinic of Navarra and corresponds to a meta-
static bone implant from an adult patient with a
metastatic bone implant. The clinical characteristics
and also the molecular hallmarks (RB1 LOH and TP53
mutation) of the cell line have been reported previously
by our group [16]. Cells were cultured in α-Minimum
Essential Medium (a-MEM) supplemented with 10%
fetal bovine serum in a humidified atmosphere contain-
ing 5% CO2 at 37 °C.
Adenovirus construction and infection
VCN-01 adenovirus presents a modified fiber protein
that confers an enhanced infectivity and expresses the
human PH20 gene that encodes for a soluble hyal-
uronidase that degrades the extracellular matrix of the
tumors [15]. Construction and method of infection of
oncolytic adenovirus VCN-01 have been described
previously [17, 18].
Animal model and experimental design
The experimental design is summarized in Fig. 1. All the
procedures involving animals performed in this study
were carried out in accordance with the guidelines of
the European Community (Council Directive 2010/63/
UE) and the Spanish Government (Real Decreto 53/
2013) and were approved by the Ethics Committee for
Animal Experimentation of the University of Navarra
(protocols 065–13 and 160–11).
Female athymic nude mice (NCr nude, Taconic Farms,
Inc.), 8–9 weeks of age and between 20 and 22 g were
used in this study. Mice were socially housed (4–5 ani-
mals per cage) in individually ventilated cages in an
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air-conditioned room at 22 °C under a 12 h light/dark
cycle with access to food and tap water ad libitum dur-
ing all the experiment, except the day before PET studies
(see below).
For the orthotopic intratibial model, mice were
injected in the tibial plateau of both hindlimbs with 5 ×
105 143B cells (n = 5, 10 hindlimbs) or 531MII (n = 3, 6
hindlimbs).
To detect and examine in vivo tumoral metabolic pro-
file (Fig. 1a), [18F] FDG and Na [18F] F static PET scans
were performed in consecutive days, 30 days (143B) or
90 days (531MII) post tumor cell injections, when tu-
mors were macroscopically evident. The day after the
last PET scan, animals were euthanized by cervical dis-
location and tumors collected for histopathological ana-
lysis. As negative control, additional mice without
tumors were studied with [18F] FDG and Na[18F] F
(n = 2, 4 hindlimbs) that were used to obtain reference
values in the quantitative analysis.
To study PET usefulness for treatment assessment
(Fig. 1b), other group of mice was injected with 5 × 105
531MII cells in both hindlimbs. After 7 days, mice were
randomized in three groups: non-treated (positive con-
trol; n = 3, 6 hindlimbs) and treated with 107 (n = 5, 10
hindlimbs) or with 108 (n = 4, 8 hindlimbs) pfu of onco-
lytic adenovirus VCN-01. Virus treatment consisted of
intratumoral injections 7 and 21 days after cell implant-
ation, whereas non-treated positive control mice re-
ceived phosphate-buffered saline (PBS) injections. PET
studies for treatment monitoring were performed 80 and
90 days post tumor cells inoculation in all animals with
[18F] FDG. Additionally, two mice without tumors were
studied as negative controls. At end point, and after cer-
vical dislocation of the mice, hindlimbs/tumors were ex-
cised for histopathological analysis.
PET acquisition
For PET procedure mice were fasted overnight but
allowed to drink water ad libitum. The day of the [18F]
FDG study, mice were anesthetized with 2% isoflurane
in 100% O2 gas and [
18F] FDG (18.3 ± 0,66MBq in
80–100 μL) was injected via the tail vein. To avoid radio-
tracer uptake in the hindlimb muscle due to animal
movement, [18F] FDG uptake was performed under con-
tinuous anesthesia for 50 min. For Na [18F] F imaging,
radiotracer (18.2 ± 1.04MBq in 80–100 μL) was injected
via tail vein in awake mice 90 min before PET study. In
all studies, radiotracer uptake was performed with ani-
mals over a heating pad heated at 37 °C. PET scans were
acquired in a dedicated small animal Philips Mosaic
tomograph (Cleveland, OH), with 2mm resolution, 11.9
cm axial field of view (FOV) and 12.8 cm transaxial
FOV. Mice were placed prone on the PET scanner bed
to perform a static acquisition (sinogram) of 15 min
under anesthesia (isoflurane). Images were reconstructed
using the 3D Ramla algorithm (a true 3D reconstruc-
tion) with 2 iterations and a relaxation parameter of
0.024 into a 128 × 128 matrix with a 1 mm voxel size
Fig. 1 Experimental design. Experimental protocol design for (a) the detection and description of osteosarcoma in two different experimental
orthotopic models using [18F]FDG and Na[18F]F radiotracers and (b) the assessment of a new experimental treatment based on the use of the
oncolytic adenovirus VCN-01by [18F]FDG. “n” refers the number of tumors analyzed
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applying dead time, decay, random and scattering
corrections.
PET analysis
For PET analysis, all studies were exported and analyzed
using the PMOD software (PMOD Technologies Ltd.,
Adliswil, Switzerland). Images were expressed in stan-
dardized uptake value (SUV) units, using the formula
SUV = [tissue activity concentration (Bq/cm3)/injected
dose (Bq)] × body weight (g). An expert observer deter-
mined the presence of tumors detected by each radio-
tracer. After this qualitative detection, a semi-
quantitative analysis was performed drawing a volume of
interest (VOI) containing the entire hindlimb. For [18F]
FDG quantitative analysis, maximum voxel intensity
within the VOI (SUVmax) was recorded. For Na [18F] F
evaluation, and in order to normalize tumor uptake re-
spect to physiological uptake in normal bone, a ratio be-
tween tumor SUVmax and hip SUVmax was calculated
(SUVmax ratio), considering SUVmax of the hip the
value of physiological uptake of the radiotracer. For
treatment assessment with [18F] FDG, in addition to
SUVmax values, total lesion glycolysis (TLG) was calcu-
lated as the product of mean SUV within the VOI and
the tumor volume (cm3).
Ki-67 immunostaining
After sacrifice, hindlimbs/tumors were collected to per-
form a histopathologic characterization. Paraffin sections
(3 μm thick) were cut, dewaxed and hydrated. Sections
of all tumors were stained with hematoxylin and eosin
for histologic evaluation. Immunohistochemical staining
for Ki-67 (rabbit monoclonal, clone SP6, 1:100, NeoMar-
kers; RM-9106) was performed on those tumors/hin-
dlimbs of treated mice, using the EnVisionTM+ System
(Dako, Glostrup, Denmark) according to the manufac-
turer’s recommendations.
Statistical analysis
Statistical analysis was performed with STATA software
(StataCorp, Texas, USA). For each animal, two tumors
were created (one for each hindlimb). Every tumor was
considered an independent value in statistical analysis
without taking into account intra-animal correlation.
Since not all mice developed tumors in both hindlimbs,
sensitivity and specificity of [18F] FDG and Na [18F] F for
tumor detection were evaluated comparing qualitative
PET results with the presence of primary tumors de-
tected after mice sacrifice only in mice used for ortho-
tropic models. [18F] FDG SUVmax and Na [18F] F
SUVmax ratio values between 531MII and 143B models
and negative control animals were compared by the
nonparametric Kruskal–Wallis test followed by Bonfer-
roni post hoc test. To evaluate [18F] FDG usefulness for
treatment assessment, SUVmax and TLG values be-
tween negative controls, PBS positive controls and two
experimental groups treated with 107 or 108pfu of ade-
noviruses were analyzed at different time points using
the nonparametric Kruskal–Wallis test and Bonferroni
post hoc test. Wilcoxon signed-rank test was applied to
study differences between both [18F] FDG studies in the
same group.. All data were expressed as mean ± standard
deviation (SD) and p-values lower than 0,05 considered
as statistically significant.
Result
Description of the tumors
The use of [18F] FDG and Na [18F] F allowed to describe
the metabolic pattern of tumors, that was different be-
tween both orthotopic models (Fig. 2). The cell line 531
MII generated tumors with different phenotypes (n = 5),
some with high [18F] FDG and low Na [18F] F uptake
and others with the opposite pattern (Fig. 2a, b and
Additional file 1: Figure S1). On the other hand, all the
tumors from cell line 143B showed a very high [18F]
FDG signal, but a very slight or no Na [18F] F uptake
(n = 10) (Fig. 2c, d and Additional file 1: Figure S1). Im-
portantly, histopathological analysis confirmed that [18F]
FDG and Na [18F] F uptake corresponded to highly cel-
lular and osteoid-rich tumors, respectively (Fig. 2e, f, g
and Additional file 1: Figure S1).
Quantitative analysis of the [18F] FDG images (Fig. 3a)
demonstrated that [18F]FDG SUVmax values were statis-
tically significant higher (p < 0.001) for both models
compared with negative control animals (n = 2, 4 hin-
dlimbs) (531MII: 1.73 ± 0.29; 143B: 3.08 ± 0.48; C -: 0.46
± 0.05). In turn, [18F] FDG uptake was also significantly
higher in 143B than in 531MII tumor models
(p < 0.001). On the other hand, 531MII tumors showed a
heterogeneous Na [18F] F uptake, ranging from negative
tumors to tumors with very high signal and with SUV-
max ratio values higher than in 143B tumors, which
showed a very slight signal (531MII: 2.02 ± 0.62 vs. 143B:
0.88 ± 0.09) (Fig. 3b). Differences in Na[18F]F values be-
tween both models were statistically significant
(p < 0.01). Only 531MII tumors showed a statistically
higher uptake compared with negative control values
(0.37 ± 0.04) (p < 0.001), whereas 143B values did not dif-
fer from the healthy control (p = 0.096).
Tumor detection
Qualitative analysis of the images showed an excellent
correspondence between [18F]FDG uptake and gross
examination of the tumors (Fig. 4a and b). In this way,
in spite of a different degree of uptake, all tumors de-
rived from both cell lines were detected using [18F]FDG
(531MII, 5/5 tumors and 143B, 10/10 tumors), with a
sensitivity and specificity of 100%. However, Na[18F]F
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Fig. 2 Metabolic description of the tumors using [18F]FDG and Na[18F]F. Representative PET studies obtained in orthotopic models of osteosarcoma. A
and B images correspond to the same animal injected with 531MII cell line, whereas C and D images were obtained from other animal injected with
143B line. The use of [18F]FDG (a, c) or Na[18F]F (b, c) allowed detection of different metabolic patterns in the tumors. Images from sections stained
with hematoxylin-eosin from each tumor (e, f, g) confirmed that the 531MII cell line created heterogeneous tumors with osteoblastic or osteolytic
phenotypes, whereas the 143B model generated osteolytic tumors with high cellularity. Red arrows: tumors detected by PET; asterisk: physiological
utptake of Na[18F]F in knees; b: bladder showing physiological excretion of radiotracer
Fig. 3 Semi-quantitative analysis of [18F]FDG or Na[18F]F uptake in osteosarcoma models. Box plots showing quantitative analysis of [18F]FDG (a)
or Na[18F]F (b) uptake in osteosarcoma models. For each radiotracer, data of semi-quantitative indexes were compared between negative control
mice without tumors (C-) and 531MII and 143B tumors. ** p < 0.01; ***p < 0.001
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was not able to detect all osteosarcomas (531MII, 3/5
tumors and 143B, 5/10 tumors), so the sensitivity was
around 70% in both models, with a specificity of 100%
(Fig. 4a, c).
Treatment assessment
As the sensitivity of [18F]FDG was 100% and significantly
better than that of Na[18F]F, treatment assessment with
the oncolytic adenoviruses was monitored in 531MII
xenograft model only by [18F]FDG studies. PET studies
were evaluated at two time points (80 and 90 days after
cell implantation) by two semiquantitative indexes, SUV-
max and TLG (Fig. 5 and Table 1).
Visual analysis of [18F]FDG PET detected tumors
only in non-treated mice and the group treated with
107 pfu VCN-01 (Fig. 5a). In the first PET study (day
80), [18F]FDG detected tumors in all non-treated
mice (n = 3, 6 hindlimbs), showing a statistically sig-
nificant increase in SUVmax and TLG indexes with
respect to negative control mice (Table 1 and Fig. 5b
and c). No tumors were detected in mice treated 108
pfu, showing a similar [18F]FDG uptake to that of
negative control animals and pointing out the ab-
sence of tumor growth. In the group treated with
107 pfu VCN-01, [18F]FDG uptake was heteroge-
neous, detecting only 3 out of 10 possible tumors.
At the end of the experiment (day 90), both TLG
and SUVmax indexes in non-treated tumors in-
creased, showing a statistically significant growth as
compared with the first PET study (Fig. 5b and c,
Table 1). As expected, animals treated with 108 pfu
continued to show no sign of [18F]FDG uptake. As a
group, mice treated with 107 pfu VCN-01 showed
decreased [18F]FDG uptake and SUVmax and TLG
indexes. Gross examination of hindlimbs confirmed
that 107 pfu dose exerted a heterogeneous response
and that only 3 tumors developed, whereas mice
treated with the higher dose of VCN-01 had no evi-
dence of tumors.
Histopathological studies and Ki-67 immunohisto-
chemistry at the end of the experiment validated PET
findings and confirmed the presence of all tumors
Fig. 4 Tumor detection by [18F]FDG and Na[18F]F. Gross examination of osteosarcoma tumors developed in mice with the 531MII cell line (a) and
PET images obtained with [18F]FDG (b) or Na[18F]F (c). Images on the left and on the right side of the figure correspond to two different animals
(case 1 and case 2). PET with [18F]FDG clearly distinguished the presence or absence of tumors (red arrows). On the other hand, Na[18F]F failed to
reveal some tumors. Red positive sign: true positive; green negative sign: true negative; yellow asterisk: false negative
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detected by [18F]FDG PET (Fig. 5d). Hematoxylin and
eosin staining showed that the tumors in non-treated
mice with a high cellularity also presented a high level of
Ki-67 staining, corresponding to an elevated number of
proliferating cells. Tumors in the group treated with 107
pfu VCN-01 were similar, albeit with a slight decrease of
Ki-67 staining.
Discussion
This work aimed to confirm the potential of PET
metabolic imaging in the study and management of
osteosarcomas by studying two orthotopic murine
models. In the first part of the study, we confirmed
the ability of PET to noninvasively describe the
heterogeneous tumor metabolism observed in other
Fig. 5 Performance of [18F]FDG as PET radiotracer for the evaluation of treatment with the oncolytic adenovirus VCN-01. (a) [18F]FDG PET images
showing tumor evolution in the osteosarcoma model created with 531MII cell line. Images correspond to the non-treated positive control group
(PBS control) and the two treatment groups with different adenovirus doses (virus 107 pfu and 108 pfu) studied at two different time points (PET
1 and PET 2). Red arrows point out tumors detected by PET (b and c). Box plot graphs for quantitative analysis of the [18F]FDG images, showing
the evolution of SUVmax and TLG data between experimental groups over time and compared with negative controls without tumors (C-). $ symbol
represent significant differences between data of the same group in the two time points ($ p < 0,05). * symbols represent statistically significant differences
respect C- (* p < 0.05, ***p < 0,001). (d) Images of immunohistological analysis corresponding to the right hindlimbs of the same animals showed in (A),
and obtained after the sacrifice at the end of the experiment (90 days). Serial sections were stained with hematoxylin and eosin and Ki-67, which detects
cellular proliferation. Scale bars, 300 μm
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similar animal models [10]. For this purpose, multi-
tracer studies have been performed with [18F]FDG
and Na[18F]F radiotracers, which inform respectively
about the proliferative state of the tumors and the
presence of osteoid or immature bone matrix, a
histologic feature of osteosarcomas. The two cell
lines used in this study generated two type of tu-
mors with different metabolic characteristics. The
commercial cell line 143B produced highly cellular
tumors, mimicking osteolytic phenotype, that were
detected by [18F]FDG showing a very high uptake
for this radiotracer, but with very limited or no
Na[18F]F uptake, thus confirming the results ob-
tained by Campanile et al. [10]. Of great interest are
the results obtained with the osteosarcoma cell line
531MII, established from a patient with metastatic
disease. This cell line was able to generate tumors
with different phenotypes, probably due to clonal
selection [19], and hence resembling more closely
what occurs in patients. This phenotype diversity,
validated in histological studies, was perfectly de-
scribed in a noninvasive manner by PET imaging.
The most osteoblastic tumors showed higher
Na[18F]F uptake and less [18F]FDG uptake, whereas
mainly osteolytic tumors presented more avidity for
[18F]FDG and lower or no uptake of Na[18F]F. This
ability to describe in vivo tumoral metabolism is a
feature of PET imaging that could be employed to
personalize the treatments based on the biology of
the tumors, a concept behind the new strategies
against cancer [20, 21].
Although multitracer studies were able to determine
the phenotype of the tumors, it should be noted that
only [18F]FDG detected all tumors in both models,
with a sensitivity and a specificity of 100%. Na[18F]F
uptake was hampered due to some highly cellular tu-
mors, especially those generated by the 143B cell line,
so the sensitivity for this radiotracer was 70%, with a
specificity of 100%. This fact may vary at the clinical
setting, in which one of the histological hallmarks of
osteosarcoma is osteoid production, although in some
cases cartilage matrix or fibrous tissue can be pre-
dominant [22].
The other main objective of this work was to ex-
plore the utility of PET imaging to assess the efficacy
of treatment. In the clinical setting, [18F]FDG PET is
used as an early predictor of response to neoadjuvant
chemotherapy in osteosarcoma and other type of tu-
mors [8, 23], and this ability could be used by re-
searchers to monitor the response of new
experimental treatments in animal models in a nonin-
vasive manner. In this case, the excellent sensitivity of
[18F]FDG in our animal models prompted us to use
this radiotracer to assess the effect of the oncolytic
adenovirus VCN-01 in the 531MII orthotopic model.
Oncolytic adenoviruses are genetically modified to in-
fect and destroy the tumor cells in a selective manner
without affecting other tissues [24]. In particular,
VCN-01 adenovirus replicate in tumors with a defect-
ive RB1 pathway and enhance its infectivity through a
modified fiber and the expression of a soluble hyal-
uronidase that degrades extracellular matrix. This new
and promising therapy has previously been studied by
our group in orthotopic and lung metastatic mice
models of osteosarcoma, demonstrating that it exerts
a significant and potent antitumor effect in both
models [15].
PET [18F]FDG studies allowed the monitoring of
the response to this therapy in the orthotopic model.
Visually, the first image study performed at day 80
demonstrated that the virus produced an antitumor
effect in a dose-dependent manner. Interestingly, in
this point-time, PET showed that no tumors had been
developed in animals treated with VCN-01 at 108 pfu,
whereas the low dose of 107 pfu was able to avoid
tumor growth only in some cases. The second PET
study, performed at the end of the experiment (day
90), confirmed the growth of the tumors in the
non-treated group and a decrease in the signal in the
tumors treated with 107 pfu. As previously published
by Martinez-Vélez et al. [15], molecular techniques
demonstrated that the antitumor effect observed in
treated groups was caused by the action of VCN-01.
Expression of the adenovirus fiber and PH20 mRNA
were detected in mice treated with VCN-01, and this
expression was higher in tibiae treated with 108 pfu
Table 1 Treatment assessment. Semi-quantitative analysis of [18F]FDG uptake
SUVmax PET 1 SUVmax PET 2 TLG PET 1 TLG PET 2
C - 0.65 ± 0.62 0.58 ± 0.10 0.11 ± 0.37 0.07 ± 0.27
PBS control 1.32 ± 0.14* 1.76 ± 0.29$,*** 0.42 ± 0.17* 0.79 ± 0.37$,***
VCN-01 107pfu 1.19 ± 0.75 0.86 ± 0.41$ 0.27 ± 0.26 0.16 ± 0.14$
VCN-01 108 pfu 0.70 ± 0.23 0.58 ± 0.13 0.12 ± 0.48 0.08 ± 0.30
Summary of semi-quantitative analysis of [18F]FDG uptake in negative controls (C-), non-treated PBS controls and VCN-01 treated groups (107 and 108 pfu doses)
in the different time points (PET 1 and PET 2) after treatment. Data of SUVmax and TLG indexes are shown as mean ± SD. $ symbol represents significant
differences between PET 1 and PET 2 in the same group ($ p < 0.05). * symbols represent statistically significant differences compared to C- in the same time
point (* p < 0.05, ***p < 0.001)
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than those treated with 107 pfu. Moreover, viral pres-
ence was demonstrated at the end of the experiment,
so the decrease in [18F]FDG uptake between the two
point-times in the 107 pfu treated group could be
showing that the action of the adenovirus continues
along time, even when treatment was administered
long time before (months). The increase over time in
VCN-01 viral genome levels in tumor samples after a
single administration of adenovirus has previously
been demonstrated in other animal models [25].
[18F]FDG images of the tumors were quantitatively ana-
lyzed by means of two semi-quantitative indexes, SUVmax
and TLG. SUVmax reflects the highest metabolic activity
of the tumor, whereas TLG represents the overall metab-
olism of the malignant lesion, combining information
about the volume and the metabolic activity of the tumor.
Some authors suggest that TLG reflects more accurately
the real tumor burden [26, 27] and could be considered as
a better prognostic measure than SUVmax. In this model,
both SUVmax and TLG indexes increased overtime in tu-
mors of the non-treated group, (reflecting the growth of
tumors), whereas in the group treated with 107 pfu
VCN-01 such indexes decreased because the treatment
continued its effect along time. Due to the small number
of tumors obtained after the treatment with VCN-01, fur-
ther studies are needed to explore the utility of these in-
dexes and how they reflect the mechanism of action of the
treatments. Finally, although in this study Na[18F]F has
been discarded for treatment evaluation, it could be of
great interest to include this radiotracer in future studies
to ascertain whether hyaluronidase produced by VCN-01
is able to degrade extracellular osteoid and change the
metabolic profile of tumors from osteoblastic to a more
osteolytic phenotype.
Conclusions
In conclusion, this study demonstrates that PET stud-
ies with [18F]FDG and Na[18F]F can describe in vivo
osteosarcoma phenotypes since the metabolic patterns
correlate with the histological appearance of the tu-
mors. We have also proven in vivo that different
orthotopic murine models of osteosarcoma lead to tu-
mors with diverse metabolic patterns, and that the
cell line 531MII is able to generate tumors with dif-
ferent phenotypes. Since in those osteosarcoma
models not all tumors produced abundant osteoid,
[18F]FDG demonstrated a better sensitivity for tumor
detection. This tracer could monitor and prove the
treatment efficacy of the oncolytic adenovirus
VCN-01, that avoided tumor establishment and
growth in a dose dependent manner. Further studies
are needed to explore the PET usefulness in the man-
agement of osteosarcomas in the clinical setting.
Additional file
Additional file 1: Figure S1. Metabolic description of the tumors using
[18F]FDG and Na[18F]F. Three cases of tumors obtained in orthotopic
models of osteosarcoma. Figure shows PET studies from the same animal
performed with [18F]FDG and Na[18F]F, as well as sections of the
histopathological analysis stained with hematoxylin-eosin. PET images show
the animal in supine position, so the right tibia is to the left of the image
and vice versa. Red arrows: tumors detected by PET; asterisk: physiological
utptake of Na[18F]F in knees; b: bladder showing physiological excretion of
radiotracer. (TIF 4289 kb)
Abbrevations
18F-FDG: 2-deoxy-2-[18F]fluoro-D-glucose.; PBS: Phosphate buffered saline.;
PET: Positron emission tomography.; pfu: Plaque-forming unit.; SUV: Standardized
uptake value.; SUVmax: Maximum standardized uptake value.; TLG: Total lesion
glycolysis.
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